Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F DONOHUE

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Southern Medical Journal|June 1, 1980
Phycomycosis: a cause of bronchial obstructionJ F Donohue, R J Scott, D H Walker, et al.
Pulmonary Circulation|January 17, 2017
Tadalafil therapy for sarcoidosis-associated pulmonary hypertensionH J Ford, R P Baughman, R Aris, et al.
Respiratory Medicine|July 9, 2013
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDJ F Donohue, M R Maleki-Yazdi, S Kilbride, et al.
Urology|January 18, 2006
Use of expired breath ethanol measurements in evaluation of irrigant absorption during high-power potassium titanyl phosphate laser vaporization of prostateN J Barber, G Zhu, J F Donohue, et al.
Chest|November 18, 2000
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study GroupR Casaburi, D D Briggs, J F Donohue, et al.
The American Review of Respiratory Disease|May 1, 1989
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center studyN J Gross, T L Petty, M Friedman, et al.
Archives of Internal Medicine|May 13, 1996
Characteristics predicting incorrect metered-dose inhaler technique in older subjectsS L Gray, D M Williams, C C Pulliam, et al.
The New England Journal of Medicine|July 24, 1980
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factorsP A Aronin, M S Mahaley, S A Rudnick, et al.
Therapeutic Advances in Respiratory Disease|January 7, 2009
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceJ F Donohue, N A Hanania, K A Sciarappa, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 29, 2011
Ambrisentan for sarcoidosis associated pulmonary hypertensionM A Judson, K B Highland, S Kwon, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Southern Medical Journal|June 1, 1980
Phycomycosis: a cause of bronchial obstructionJ F Donohue, R J Scott, D H Walker, et al.
Pulmonary Circulation|January 17, 2017
Tadalafil therapy for sarcoidosis-associated pulmonary hypertensionH J Ford, R P Baughman, R Aris, et al.
Respiratory Medicine|July 9, 2013
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDJ F Donohue, M R Maleki-Yazdi, S Kilbride, et al.
Urology|January 18, 2006
Use of expired breath ethanol measurements in evaluation of irrigant absorption during high-power potassium titanyl phosphate laser vaporization of prostateN J Barber, G Zhu, J F Donohue, et al.
Chest|November 18, 2000
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study GroupR Casaburi, D D Briggs, J F Donohue, et al.
The American Review of Respiratory Disease|May 1, 1989
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center studyN J Gross, T L Petty, M Friedman, et al.
Archives of Internal Medicine|May 13, 1996
Characteristics predicting incorrect metered-dose inhaler technique in older subjectsS L Gray, D M Williams, C C Pulliam, et al.
The New England Journal of Medicine|July 24, 1980
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factorsP A Aronin, M S Mahaley, S A Rudnick, et al.
Therapeutic Advances in Respiratory Disease|January 7, 2009
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceJ F Donohue, N A Hanania, K A Sciarappa, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 29, 2011
Ambrisentan for sarcoidosis associated pulmonary hypertensionM A Judson, K B Highland, S Kwon, et al.
Pageof 3